INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

December 2025 Volume 4 Number 6 33-37

Received Date: October 20, 2025 Accepted Date: November 11, 2025 Published Date: December 01, 2025

Probiotic Use in Irritable Bowel Syndrome (IBS) Comprehensive Review

Wejdan Yousef Alkhamis [1], Yasamiyan Alolaywat [2], Zahra Habeeb Al-Zara [3], Sumayyah Ibrahim Aljafar [4], Yaqoub Yousef Almubarak [5], Abduladhim Yassin Almakki [5], Yaqoub Yousef Alatiyyah [6], Zainab Gawad Almajed [7], Rawabi Ali Alfarhan [7], Sara Ahmed Alowdh [8], Ali Mohammed Busaleh [9], Haidar Mahdi Albeladi [10], Osamah Abdullah Alnajm [11], Fatimah Abdrab Alrasool Alghazal [11], Zainab Abdulmuhsin Alabduljabbar [11]

1. Maternity And Children Hospital
2. Dammam Medical Complex (DMC)
3. King Fahad Specialist Hospital Dammam
4. Mental Hospital In Alahsa
5. Aljafer General Hospital
6. Center Of Blood Hereitdy Diseases
7. Prince Saud Bin Jalwei Hospital
8. KING FAISL GENERAL HOSPITAL
9. ERADAH – Mental Health Complex
10. Aljaber Kidney Center

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder linked to gut-brain axis dysfunction and intestinal dysbiosis. Probiotics, defined as live microorganisms with health benefits, have emerged as a prominent therapeutic strategy targeting this microbial imbalance. This comprehensive review synthesizes current evidence on the mechanisms, clinical efficacy, practical application, and future directions of probiotic therapy for IBS.A narrative synthesis of key meta-analyses, systematic reviews, and randomized controlled trials was conducted, with a focus on strain-specific effects and clinical guidelines. The pathophysiology of IBS involves visceral hypersensitivity, altered motility, low-grade inflammation, and dysbiosis. Probiotics are proposed to ameliorate symptoms by modulating the microbiota, enhancing epithelial barrier function, regulating immune responses, and influencing the gut-brain axis. Meta-analyses indicate a modest but significant benefit for probiotics over placebo in improving global IBS

symptoms (RR 1.53) and reducing abdominal pain (RR 1.79), though the certainty of evidence is often low due to significant heterogeneity. Efficacy is **strain-specific**, with particular evidence for *Bifidobacterium infantis* 35624, *Lactobacillus plantarum* 299v, and *Saccharomyces boulardii* CNCM I-745. The most consistent improvements are seen in bloating and abdominal pain. Probiotics are generally safe for immunocompetent individuals and are positioned as a second-line or adjunctive therapy within a holistic management plan. Probiotic therapy represents a rational and moderately effective intervention for IBS, primarily for global symptom relief, pain, and bloating. Success depends on selecting strains with documented clinical evidence. Future research should focus on personalized approaches, long-term outcomes, and the development of symbiotic and postbiotics to better define and optimize the role of microbial therapeutics in IBS management.

Keywords: Irritable Bowel Syndrome; Probiotics; Dysbiosis; Gut-Brain Axis; *Bifidobacterium*; *Lactobacillus*; Microbiome.

1. Introduction

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain associated with defecation or a change in bowel habits, in the absence of detectable organic disease [1]. It affects approximately 4-10% of the global population, significantly impairing quality of life and imposing a substantial economic burden [2]. The pathophysiology of IBS is multifactorial, involving visceral hypersensitivity, altered gut-brain axis communication, abnormal gastrointestinal motility, low-grade mucosal inflammation, and notably, **intestinal dysbiosis**—an imbalance in the composition and function of the gut microbiota [3].

Probiotics, defined by the World Health Organization as "live microorganisms which when administered in adequate amounts confer a health benefit on the host," have emerged as a prominent therapeutic strategy targeting this dysbiosis [4]. This review synthesizes current evidence on the mechanisms, efficacy, clinical application, and future directions of probiotics in IBS management.

2. Mechanisms of Action in IBS

Probiotics are theorized to ameliorate IBS symptoms through several interconnected mechanisms:

- **Microbial Modulation & Barrier Function:** Probiotics can competitively exclude pathogens, produce antimicrobial substances (e.g., bacteriocins), and enhance the intestinal epithelial barrier by upregulating tight junction proteins [5]. This may reduce bacterial translocation and subsequent immune activation.

- **Immune Regulation:** Certain strains modulate the host immune response by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-8) and promoting anti-inflammatory pathways (e.g., increasing IL-10, TGF-β) [6]. This is particularly relevant in IBS patients with post-infectious onset or low-grade inflammation.

- **Neuromodulation of the Gut-Brain Axis:** Probiotics (often termed "psychobiotics") can influence central nervous system function via the vagus nerve and by producing neuroactive metabolites like gamma-aminobutyric acid (GABA) and serotonin precursors [7]. This can reduce visceral hypersensitivity and pain perception.

- **Metabolic Effects:** They ferment dietary fibers to produce short-chain fatty acids (SCFAs) like butyrate, which serve as an energy source for colonocytes and exert anti-inflammatory effects [8]. Some strains may also influence bile acid metabolism, which affects motility and secretion.

3. Clinical Efficacy: Evidence from Meta-Analyses

The overall efficacy of probiotics in IBS is supported by meta-analyses, but the evidence is characterized by significant heterogeneity.

- **Global Symptoms and Abdominal Pain:** A 2023 update of the Cochrane systematic review concluded that probiotics as a class are more effective than placebo in achieving **global symptom improvement** (Risk Ratio [RR] 1.53, 95% CI 1.23 to 1.90) and reducing **abdominal pain** (RR 1.79, 95% CI 1.08 to 2.97) [9]. However, the authors graded the certainty of this evidence as **low**, citing high risk of bias and inconsistency across studies.

- **Symptom-Specific Outcomes:** The most robust and consistent benefits appear to be for **bloating/distension** and **flatulence**, symptoms closely tied to gas production and visceral sensation [10]. Effects on bowel habit are **strain-specific and subtype-dependent**.

- **The Challenge of Heterogeneity:** The major limitation in interpreting this data is the vast heterogeneity in **probiotic strains, doses, combinations, trial duration, and patient populations (IBS subtype)** [11]. This makes a blanket recommendation for "probiotics" impossible.

4. Strain-Specific and Formulation-Specific Effects

The clinical effect is not a class effect but is highly dependent on the specific microorganism(s) used.

- **Single-Strain Probiotics with Substantial Evidence:**
    - ***Bifidobacterium infantis 35624***: One of the most studied strains, showing efficacy in improving composite IBS symptoms, abdominal pain, bloating, and bowel movement difficulty in multiple RCTs, particularly for the mixed (IBS-M) and diarrhea-predominant (IBS-D) subtypes [12].
    - ***Lactobacillus plantarum 299v (DSM 9843)***: Shown to significantly reduce abdominal pain and bloating in IBS patients, potentially by reducing colonic inflammation and visceral sensitivity [13].
    - **Saccharomyces boulardii CNCM I-745**: A probiotic yeast with evidence for benefit in IBS-D, possibly through trophic effects on the mucosa, modulation of host immune response, and antimicrobial activity [14].
- **Multi-Strain Probiotic Formulations:** Some combinations have demonstrated superior effects in trials, potentially due to synergistic actions. Examples include specific blends of *Lactobacillus* and *Bifidobacterium* species [15]. The high-potency formulation **VSL#3** (since reformulated) showed efficacy in IBS, though its primary evidence base is in ulcerative colitis [16].

5. Clinical Application and Practical Guidelines

For clinicians and patients considering probiotic therapy:

1. **Selection:** Choose a product with a **clearly documented strain designation** (genus, species, strain) that has demonstrated efficacy in **peer-reviewed, randomized controlled trials for IBS**. The CFU count (often 1-10 x 10^9 per day) should be guaranteed through expiry.
2. **Trial Duration:** A minimum trial of **4 to 8 weeks** is necessary to assess clinical response. Benefits, if they occur, are typically seen within this period.
3. **Safety Profile:** Probiotics are generally safe for immunocompetent individuals. Common side effects are mild and transient (e.g., initial gas). They should be used with **extreme caution or avoided** in critically ill, immunocompromised, or patients with central venous catheters due to rare but serious risks of bacteremia or fungemia [17].
4. **Position in Therapy:** Probiotics are best viewed as a **second-line or adjunctive therapy** within a holistic management plan that includes first-line dietary (e.g., low-FODMAP diet, fiber) and lifestyle interventions, and may be used alongside pharmacological agents [18].

6. Limitations, Gaps, and Future Directions

- **Limitations:** Lack of long-term efficacy and safety data, unknown optimal dosing, variable regulatory standards for supplements, and significant placebo response in functional GI trials.
- **Future Directions:**
    - **Personalized Medicine:** Utilizing microbiome profiling to predict which patients are most likely to respond to specific probiotic strains [19].
    - **Mechanistic Studies:** Applying metabolomics and metagenomics to better define strain-specific mechanisms in humans.
    - **Novel Formulations:** Research into **postbiotics** (inanimate microorganisms and/or their components) and **synbiotics** (combinations of probiotics and prebiotics) may offer more stable and targeted alternatives [20].
    - **Rigorous Trial Design:** Future RCTs must be larger, longer, adhere to consensus endpoints (e.g., FDA endpoint), and clearly document probiotic characterization.

Conclusion

Probiotic therapy represents a rational, predominantly safe, and modestly effective intervention for the management of IBS, primarily targeting global symptoms, abdominal pain, and bloating. Its fundamental principle is **strain-specificity**. Successful implementation requires clinicians and patients to select a preparation with robust clinical evidence for IBS. While not a cure, probiotics are a valuable tool in the multidisciplinary approach to IBS, requiring integration with dietary, lifestyle, and when necessary, pharmacological strategies. Future research focused on personalization and mechanistic clarity will refine their role in clinical practice.

References

1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016; 150:1393-1407.

2. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology. 2021; 160:99-114.

3. Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017; 376:2566-2578.

4. Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11:506-514.

5. Ohland CL, MacNaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2010;298: G807-19.

6. Plaza-Díaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients. 2017;9(6):555.

7. Cryan JF, O'Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019; 99:1877-2013.

8. Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519-28.

9. Ford AC, Harris LA, Lacy BE, et al. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, symbiotic and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2023; 58:242-257.

10. Zhang Y, Li L, Guo C, et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016; 16:62.

11. Hungin APS, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms – an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018; 47:1054-1070.

12. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101:1581-90.

13. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-8.

14. Choi CH, Jo SY, Park HJ, et al. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011; 45:679-83.

15. Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol. 2014; 29:52-9.

16. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005; 17:687-96.

17. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60 Suppl 2: S129-34.

18. Moayyedi P, Andrews CN, MacQueen G, et al. Canadian Association of Gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS). J Can Assoc Gastroenterol. 2019; 2:6-29.

19. Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017; 152:111-123.

20. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021; 18:649-667.